[Peroxisome proliferator-actived receptor-gamma ligand troglitazone induces apoptosis in renal cell carcinoma]

Related Experiment Video

Updated: Aug 24, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Feng-guang Yang1, Zhi-wen Zhang, Dian-qi Xin

  • 1Department of Urology, Peking University First Hospital, Beijing 100034,China.

Beijing Da Xue Xue Bao. Yi Xue Ban = Journal of Peking University. Health Sciences
|April 22, 2004
PubMed
Abstract

Insights

Troglitazone, a PPAR-gamma ligand, demonstrated tumor-suppressive effects in renal cell carcinoma (RCC) by inducing apoptosis. This suggests thiazolidinediones (TZDs) could be a novel treatment for RCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) is a significant health concern with limited treatment options.
  • Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a nuclear receptor with potential roles in cancer.
  • Understanding PPAR-gamma's role in RCC is crucial for developing new therapeutic strategies.

Purpose of the Study:

  • To investigate PPAR-gamma expression in RCC cell lines.
  • To determine the effect of PPAR-gamma ligands on apoptosis in RCC cells.
  • To explore the potential of PPAR-gamma ligands as a novel RCC treatment.

Main Methods:

  • Gene and protein expression analysis of PPAR-gamma using RT-PCR and Western blot in RCC and normal kidney cell lines.
  • Induction of apoptosis in RCC cells treated with troglitazone (a PPAR-gamma ligand).
  • Assessment of apoptosis via fluorescence microscopy and DNA ladder assay, with analysis of Bcl-2 and Bax expression.

Main Results:

  • PPAR-gamma expression was significantly higher in RCC cell lines (786-O, A498) compared to normal kidney cells (HK-2, HMCC).
  • Troglitazone treatment induced apoptosis in RCC cells.
  • Troglitazone altered the expression of apoptosis-related proteins, decreasing Bcl-2 and increasing Bax.

Conclusions:

  • Troglitazone exhibits a tumor-suppressive effect on renal cell carcinoma.
  • High-affinity PPAR-gamma ligands, such as thiazolidinediones (TZDs), represent a promising avenue for novel RCC therapies.
  • Further research into TZDs could lead to effective treatments for this challenging neoplasm.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...